149 related articles for article (PubMed ID: 34839098)
21. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Padurariu M; Ciobica A; Dobrin I; Stefanescu C
Neurosci Lett; 2010 Aug; 479(3):317-20. PubMed ID: 20561936
[TBL] [Abstract][Full Text] [Related]
22. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia.
Dakhale GN; Khanzode SD; Khanzode SS; Saoji A
Psychopharmacology (Berl); 2005 Nov; 182(4):494-8. PubMed ID: 16133138
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation.
Gama CS; Berk M; Andreazza AC; Kapczinski F; Belmonte-de-Abreu P
Braz J Psychiatry; 2008 Dec; 30(4):337-40. PubMed ID: 19142408
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment.
Güneş M; Camkurt MA; Bulut M; Demir S; İbiloğlu AO; Kaya MC; Atlı A; Kaplan İ; Sir A
Clin Psychopharmacol Neurosci; 2016 Nov; 14(4):345-350. PubMed ID: 27776386
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone.
Noto C; Ota VK; Gadelha A; Noto MN; Barbosa DS; Bonifácio KL; Nunes SO; Cordeiro Q; Belangero SI; Bressan RA; Maes M; Brietzke E
J Psychiatr Res; 2015 Sep; 68():210-6. PubMed ID: 26228421
[TBL] [Abstract][Full Text] [Related]
26. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission.
Perry W; Feifel D; Minassian A; Bhattacharjie I; Braff DL
Am J Psychiatry; 2002 Aug; 159(8):1375-81. PubMed ID: 12153831
[TBL] [Abstract][Full Text] [Related]
27. Assessing the relationship between antipsychotic drug use and prolidase enzyme activity and oxidative stress in schizophrenia patients: a case-control study.
Yazla E; Cetin I; Kayadibi H
Int Clin Psychopharmacol; 2023 Nov; 38(6):394-401. PubMed ID: 37490605
[TBL] [Abstract][Full Text] [Related]
28. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
Hendouei N; Farnia S; Mohseni F; Salehi A; Bagheri M; Shadfar F; Barzegar F; Hoseini SD; Charati JY; Shaki F
Biomed Pharmacother; 2018 Jul; 103():965-972. PubMed ID: 29710513
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro.
Dietrich-Muszalska A; Olas B
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):276-81. PubMed ID: 19225991
[TBL] [Abstract][Full Text] [Related]
30. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
31. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients.
Arvindakshan M; Sitasawad S; Debsikdar V; Ghate M; Evans D; Horrobin DF; Bennett C; Ranjekar PK; Mahadik SP
Biol Psychiatry; 2003 Jan; 53(1):56-64. PubMed ID: 12513945
[TBL] [Abstract][Full Text] [Related]
32. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Pillai A; Parikh V; Terry AV; Mahadik SP
J Psychiatr Res; 2007 Aug; 41(5):372-86. PubMed ID: 16564057
[TBL] [Abstract][Full Text] [Related]
33. In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [
Holmes SE; Hinz R; Drake RJ; Gregory CJ; Conen S; Matthews JC; Anton-Rodriguez JM; Gerhard A; Talbot PS
Mol Psychiatry; 2016 Dec; 21(12):1672-1679. PubMed ID: 27698434
[TBL] [Abstract][Full Text] [Related]
34. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs.
Tsai MC; Liou CW; Lin TK; Lin IM; Huang TL
Psychiatry Res; 2013 Oct; 209(3):284-90. PubMed ID: 23497820
[TBL] [Abstract][Full Text] [Related]
35. Molindone for schizophrenia and severe mental illness.
Bagnall A; Fenton M; Lewis R; Leitner ML; Kleijnen J
Cochrane Database Syst Rev; 2000; (2):CD002083. PubMed ID: 10796464
[TBL] [Abstract][Full Text] [Related]
36. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome.
Olagunju AT; Clark SR; Baune BT
Aust N Z J Psychiatry; 2019 Jun; 53(6):509-527. PubMed ID: 30957510
[TBL] [Abstract][Full Text] [Related]
37. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia.
Skinner AO; Mahadik SP; Garver DL
Schizophr Res; 2005 Jul; 76(1):83-7. PubMed ID: 15927801
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of peripheral insulin-like growth factor 1 levels in schizophrenia.
Pejcic AV; Jankovic SM; Janjic V; Djordjic M; Milosavljevic JZ; Milosavljevic MN
Brain Behav; 2023 Jan; 13(1):e2819. PubMed ID: 36448977
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals.
Barkan T; Peled A; Modai I; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2006 Aug; 16(6):429-36. PubMed ID: 16431091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
